














JOURNAL OF VASCULAR SURGERY
July 2012236 De Martino et alFinal approval of the article: RD, JW, AP, AZ, BS, DW
Statistical analysis: RD, JW
Obtained funding: Not applicable
Overall responsibility: RD
REFERENCES
1. Kearon C. Natural history of venous thromboembolism. Circulation
2003;107(23 Suppl 1):I22-30.
2. Righini M, Bounameaux H. Clinical relevance of distal deep vein
thrombosis. Curr Opin Pulm Med 2008;14:408-13.
3. Lagerstedt CI, Olsson CG, Fagher BO, Oqvist BW, Albrechtsson U.
Need for long-term anticoagulant treatment in symptomatic calf-vein
thrombosis. Lancet 1985;2:515-8.
4. Pellegrini VD Jr, Langhans MJ, Totterman S, Marder VJ, Francis CW.
Embolic complications of calf thrombosis following total hip arthro-
plasty. J Arthroplasty 1993;8:449-57.
5. Labropoulos N, Kang SS, Mansour MA, Giannoukas AD, Moutzouros
V, Baker WH. Early thrombus remodelling of isolated calf deep vein
thrombosis. Eur J Vasc Endovasc Surg 2002;23:344-8.
6. Wang CJ, Wang JW, Weng LH, Hsu CC, Lo CF. Outcome of calf
deep-vein thrombosis after total knee arthroplasty. J Bone Joint Surg Br
2003;85:841-4.
7. Oishi CS, Grady-Benson JC, Otis SM, Colwell CW Jr, Walker RH. The
clinical course of distal deep venous thrombosis after total hip and total
knee arthroplasty, as determined with duplex ultrasonography. J Bone
Joint Surg Am 1994;76:1658-63.
8. Solis G, Saxby T. Incidence of DVT following surgery of the foot and
ankle. Foot Ankle Int 2002;23:411-4.
9. Higgins J, Green S. Cochrane handbook for systematic reviews of interven-
tions, version 5.0.2 [updated 2009]. The Cochrane Collaboration; 2009.
10. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis
JP, et al. The PRISMA statement for reporting systematic reviews and
meta-analyses of studies that evaluate health care interventions: expla-
nation and elaboration. Ann Intern Med 2009;151:W65-94.
11. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D,
et al. Meta-analysis of observational studies in epidemiology: a proposal
for reporting. Meta-analysis of Observational Studies in Epidemiology
(MOOSE) group. JAMA 2000;283:2008-12.
12. Wells G, Shea B, O’Connell D, Peterson J,Welch V, LososM, et al. The
Newcastle-Ottawa Scale (NOS) for assessing the quality of nonran-
domised studies in meta-analyses.
13. Nielsen HK, Husted SE, Krusell LR, Fasting H, Charles P, Hansen
HH. Silent pulmonary embolism in patients with deep venous throm-
bosis. Incidence and fate in a randomized, controlled trial of anticoag-
ulation versus no anticoagulation. J Intern Med 1994;235:457-61.
14. Dorr LD, Gendelman V, Maheshwari AV, Boutary M,Wan Z, LongWT.
Multimodal thromboprophylaxis for total hip and knee arthroplasty based
on risk assessment. J Bone Joint Surg Am 2007;89:2648-57. a
Dr James Debord (Peoria, Ill). Do you think your analysis











w5. Masuda EM, Kessler DM, Kistner RL, Eklof B, Sato DT. The natural
history of calf vein thrombosis: lysis of thrombi and development of
reflux. J Vasc Surg 1998;28:67-73; discussion 474.
6. Solis MM, Ranval TJ, Nix ML, Eidt JF, Nelson CL, Ferris EJ, et al. Is
anticoagulation indicated for asymptomatic postoperative calf vein
thrombosis? J Vasc Surg 1992;16:414-8; discussion 418-9.
7. Lohr JM, James KV, Deshmukh RM, Hasselfeld KA. Allastair B.
Karmody Award. Calf vein thrombi are not a benign finding. Am J Surg
1995;170:86-90.
8. Sachdev U, Teodorescu VJ, Shao M, Russo T, Jacobs TS, Silverberg D,
et al. Incidence and distribution of lower extremity deep vein thrombo-
sis in rehabilitation patients: implications for screening. Vasc Endovasc
Surg 2006;40:205-11.
9. Pinede L, Ninet J, Duhaut P, Chabaud S, Demolombe-Rague S,
Durieu I, et al. Comparison of 3 and 6 months of oral anticoagul-
ant therapy after a first episode of proximal deep vein thrombosis or
pulmonary embolism and comparison of 6 and 12 weeks of therapy
after isolated calf deep vein thrombosis. Circulation 2001;103:
2453-60.
0. Philbrick JT, Becker DM. Calf deep venous thrombosis. A wolf in
sheep’s clothing? Arch Intern Med 1988;148:2131-8.
1. Righini M. Is it worth diagnosing and treating distal deep vein throm-
bosis? No. J Thromb Haemost 2007;5(Suppl 1):55-9.
2. Righini M, Paris S, Le Gal G, Laroche JP, Perrier A, Bounameaux H.
Clinical relevance of distal deep vein thrombosis. Review of literature
data. J Thromb Haemost 2006;95:56-64.
3. Hogg K, Ashton A. Towards evidence based emergency medicine:
best BETs from the Manchester Royal Infirmary. Antithrombotic
treatment of below knee deep venous thrombosis. Emerg Med J
2003;20:364-5.
4. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, LassenMR,
et al Prevention of venous thromboembolism: American College of
Chest Physicians evidence-based clinical practice guidelines (8th edi-
tion). Chest 2008:133(6 Suppl):381-453S.
5. Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic complica-
tions of anticoagulant and thrombolytic treatment: American College
of Chest Physicians evidence-based clinical practice guidelines (8th
edition); Chest 2008:133(6 Suppl):257-98S.
6. Saarinen JP, Domonyi K, Zeitlin R, Salenius JP. Postthrombotic syn-
drome after isolated calf deep venous thrombosis: the role of popliteal
reflux. J Vasc Surg 2002;36:959-64.
7. McLafferty RB, Moneta GL, Passman MA, Brant BM, Taylor LM Jr,
Porter JM. Late clinical and hemodynamic sequelae of isolated calf vein
thrombosis. J Vasc Surg 1998;27:50-6; discussion 56-7.
8. Meissner MH, Caps MT, Bergelin RO, Manzo RA, Strandness DE Jr.
Early outcome after isolated calf vein thrombosis. J Vasc Surg 1997;26:
749-56.
ubmitted Jun 27, 2011; accepted Sep 24, 2011.
Additional material for this article may be found online
t www.jvascsurg.org.DISCUSSION
Dr Joseph Ricotta (Atlanta, Ga). How long were these
patients anticoagulated for? Was there variability between the
studies in terms of the duration of anticoagulation therapy?
Dr Randall R. De Martino. There was some variation. We
required a minimum of 30 days because most of these were
postoperative patients and that is what reporting goes to, although
I think treatment should last for at least 6 weeks. We did a
sensitivity analysis of outcomes by studies reporting 6 weeks of
anticoagulation treatment or less. There was no change in the
effect on clot propagation or PE.
Dr Ricotta. The longer the duration?
Dr De Martino. Correct.oleus plexus clots in the absence of the named tibial vessel
lots?
DrDeMartino.We did not look specifically at gastrocnemius
r soleal clots in this study. We were focused on tibial and peroneal
hrombi. I think that they may follow a similar pattern, although
e can’t make any conclusions based on this study. Other studies
hat have addressed that question and maybe a compilation of
hose studies can help identify if they are similar in characteristics.
ut I don’t know that the clinical history of them is as well defined
s is tibial and peroneal.
Dr Firas Mussa (New York, NY). Your last bullet suggests
uture studies. Can you elaborate on design of those studies?Dr De Martino. I think there is still clinical equipoise as to
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Volume 56, Number 1 De Martino et al 237the data and the studies that are available, I think that there is still
a debate about this. I think clinical randomized trials will need to
assess the benefits and the harms of treatment, including bleeding,
mortality rates, and post-thrombotic syndrome. I am aware of one
ongoing clinical study in Europe, but I am unaware of the current
enrollment status. I was told yesterday in discussion, the University
of Washington has applied for a grant to perform a randomized
trial for this, and we hope that that will be funded and shed light on
this topic.
Dr Cynthia Shortell (Durham, NC). It is no surprise that
anticoagulation prevents thrombotic complications of calf vein
clot. The question has always been, when is the risk of anticoagu-
lation worth the benefit? And in calf vein thrombosis, that issue
gets down to what the risks of those patients are. One would intuit
that high-risk patients with calf clots, such as neurosurgical patients
or immobile patients, would be at higher risk, but that’s unknown
at this point. Did any of the studies that you included contain that
information? And if so, do you think you could use it to help us
identify those patients with calf clot that would really benefit from
anticoagulation?
Dr De Martino. I think we agree that there are patients who
are at higher risk. Several of these studies did try to identify specific
risk factors that would identify those patients with thrombi that are
going to propagate or cause PE. The most consistent risk factor
identified was inpatient status. Many other patient-level variables
that they were able to analyze were not predictive in their analyses.
We didn’t include that type of review in the present study, but that
is what I have been able to extract from the data that is available to
date.
DrMarkMeissner (Seattle, Wash). I was somewhat surprised
that although bleeding was heterogeneous, pulmonary embolism
and thrombus propagation was remarkably homogeneous. I think
this is surprising, because perhaps even more so than with proximal
vein thrombosis, calf vein thrombosis is often perceived to be a
heterogeneous disease with the risk of complications based on the
underlying risk factors for thrombosis. Your analysis seems to imply
that all calf vein thrombi should be treated as equal, which may not
be correct. Can you explain the homogeneity of your findings?
Dr De Martino: In regards to PE and clot propagation, I
think our pooled summary was homogeneous because of our strict
entry criteria. There are other studies reported on calf DVT that
were excluded because they didn’t meet this criteria. I think that
helped in creating a homogeneous estimate.
i
oThemajority of studies did report on PE and clot propagation.
ery few studies reported bleeding andmortality complications, so
he data that we were able to extract were sparse and spread across
ight studies, where only two to three may have contributed to the
ata, and I think that that affected our ability to make a homoge-
eous summary effect.
I think that while we were able to make a homogeneous study
ffect, we acknowledge that the strength of our findings comes
rom the quality of the studies that they were derived from. And so
robust clinical trial will really answer this question in the best light
ossible.
Dr Peter Gloviczki (Rochester, Minn). Did you notice a
ifference in symptomatic and asymptomatic calf vein thrombosis,
r were all these patients symptomatic?
Dr De Martino. We didn’t perform a formal subgroup anal-
sis of studies that were symptomatic or asymptomatic. Approxi-
ately half of the studies identified their patients as symptomatic,
wo of those four being the randomized controlled trials. But we
re unable to make a comment about whether the symptomatic
tatus does make a difference.
DrGloviczki.Andwas the diagnosis of PEmade using similar
echniques in these studies?
DrDeMartino.The diagnosis of PE was similar in all but one
tudy, which used a combination of V/Q scan and clinical diagno-
is based on patients with a sudden death that was preceded by
apid leg swelling. And so it was felt that that was a clinical
iagnosis of PE and we did include that.
Dr Roger Shinnerl (Evansville, Ind). I was wondering if you
ould please tell me if I am wrong, but I was left with the distinct
mpression, after looking at your data briefly, that all of the positive
esults were out of one study, the Pellegrini study. And that
isturbs me. Does that not make that study an outlier? And even if
ot, should we really be endorsing that finding with the results of
pooled analysis?
Dr De Martino. That one study was a nested case-control
tudy within a randomized trial. While they did identify a lot of
utcomes, I do not think that their methods were any different
han the other randomized trial that would make me think that
hey should be excluded or be an outlier. I think the fact that
ur summary of facts remained homogeneous despite their
nclusion attests that it was appropriate to include them within
ur analysis.
